Evidence map›Paper›PMID 18552823›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2008

Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.

Bonnie E Gould Rothberg, Christopher B Moeder, Harriet Kluger, Ruth Halaban, David E Elder, George F Murphy, Alexander Lazar, Victor Prieto, Lynn McDivitt Duncan, David L Rimm

Open access · greenAbstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Pathology and Molecular Biology of Melanoma.Current issues in molecular biology · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Bonnie E Gould RothbergDepartment of Pathology, Yale University School of Medicine, New Haven, CT 06520-8023, USA.
Christopher B Moeder
Harriet Kluger
Ruth Halaban
David E Elder
George F Murphy
Alexander Lazar
Victor Prieto
Lynn McDivitt Duncan
David L Rimm
Yale University · USThe University of Texas MD Anderson Cancer Center · USBrigham and Women's Hospital · USMassachusetts General Hospital · USUniversity of Pennsylvania · US

Funding

Yale SPORE in Skin CancerP50CA121974 · NCI · YALE UNIVERSITY · PI DAVID F STERN · 2006 to 2026
$43.9M
Predicting Metastasis in MelanomaR01CA114277 · NCI · YALE UNIVERSITY · PI RIMM, DAVID L · 2006 to 2013
$2.1M
NCI NIH HHS 1P50 CA121974NCI NIH HHS P50 CA121974NCI NIH HHS R0-1 CA01142777NCI NIH HHS R01 CA114277
6 · The paper itself

Abstract

HMB45 is a mouse monoclonal antibody raised against Pmel17/gp100, a melanoma-specific marker, which is routinely used in the diagnosis of primary cutaneous malignant melanoma. The standard expression pattern for a positive HMB45 staining result on immunohistochemistry is based upon the results of chromogenic-based methods. We re-evaluated the patterns of HMB45 staining across the 480-core 'SPORE melanoma progression array' containing lesions representing the spectrum of melanocytic lesions ranging from thin nevus to visceral metastasis using the fluorescence-based staining technique and automated quantitative analysis (AQUA) of the obtained digital images. The methods validated the expected cytoplasmic HMB45 staining pattern in 70/108 malignant lesions and in the epithelial components of nevus specimens. However, the fluorescence-based approach revealed a nuclear gp100 localization present in the dermal component of all nevi that was not seen before. This nuclear localization could not be observed on routine chromogenic stains, because the standard hematoxylin nuclear counterstain overwhelms the weak nuclear HMB45 stain. The thin (0.450+/-0.253) and thick (0.513+/-0.227) nevi had strongly positive mean ln(nuclear/non-nuclear AQUA score ratios), which are significantly higher than those from the group of malignant lesions (P<0.0001). This finding was reproduced on a smaller but independent progression array composed of nevi and melanomas from the Yale Pathology archives (P<0.01). The odds ratio associated with a sample being a nevus was 2.24 (95% CI: 1.87-2.69, P<0.0001) for each 0.1 unit increase of the ln(nuclear/non-nuclear AQUA score ratio) to yield an ROC curve with 0.93 units of area and a simultaneously maximized sensitivity of 0.92 and specificity of 0.80 for distinguishing benign nevi from malignant melanomas. On the basis of this preliminary study, we propose that the ratio of nuclear to non-nuclear HMB45 staining may be useful for diagnostic challenges in melanocytic lesions.

Indexed as

Antigens, NeoplasmBiomarkers, TumorCell NucleusDiagnosis, DifferentialFluorescent Antibody Technique, Indirectgp100 Melanoma AntigenHumansImage Processing, Computer-AssistedImmunoenzyme TechniquesMelanomaMelanoma-Specific AntigensMembrane GlycoproteinsNeoplasm ProteinsNevus, PigmentedSkin NeoplasmsTissue Array AnalysisAntigens, NeoplasmBiomarkers, Tumorgp100 Melanoma AntigenMelanoma-Specific AntigensMembrane GlycoproteinsNeoplasm ProteinsPMEL protein, humanPmel protein, mouse

Identifiers

PMID18552823
PMCPMC2570478
OpenAlexW2029681400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.